Cibus Announces Public Offering to Fuel Growth
Cibus, Inc. (Nasdaq: CBUS), an innovative player in agricultural biotechnology, has announced an impressive public offering priced at $1.75 per share. This offering involves 15,714,285 shares of Class A Common Stock and is expected to generate approximately $27.5 million, supporting the company's ambitious growth strategies.
Details of the Public Offering
The offering includes shares intended for various institutional and strategic investors, fostering strong community and industry ties. Notably, 5,714,286 shares are designated for Cibus’ board chairman. All shares are to be sold directly by the company, ensuring that the proceeds substantially benefit its goals.
Expected Use of Proceeds
With the anticipated funding, Cibus plans to enhance its capabilities in developing critical weed management productivity traits in rice. Additionally, these funds will assist in furthering general corporate purposes and working capital, the cornerstone of its long-term financing vision.
Working with Alliance Global Partners
A.G.P./Alliance Global Partners is taking a lead role as the sole placement agent for this offering. Their expertise is expected to streamline the process and ensure successful engagement with potential investors.
Regulatory Compliance and Transparency
This public offering aligns with the regulations set forth by the U.S. Securities and Exchange Commission. The effective shelf registration, filed in June 2023 and approved later that year, ensures that Cibus operates within the legal framework required for such offerings. The company has committed to transparency, including making all relevant information readily accessible to potential investors.
About Cibus
Cibus stands at the forefront of agricultural innovation, focusing on gene editing to develop resilience in major crops. The company's mission revolves around enhancing agricultural productivity while sustainably addressing challenges such as pests and diseases—a sector impacting the global economy significantly. Cibus is not merely a seed company; it leverages cutting-edge technology to partner with seed companies, proposing an efficient and cost-effective means of developing advanced crop traits.
Company Contacts
For further information regarding the public offering or corporate inquiries, Cibus encourages stakeholders to reach out to its dedicated investor and media relations teams. Key contacts include:
Investor Relations
Karen Troeber
Email: ktroeber@cibus.com
Phone: 858-450-2636
Media Relations
Colin Sanford
Email: colin@bioscribe.com
Phone: 203-918-4347
Frequently Asked Questions
What is the purpose of the public offering?
The funds will primarily support development in weed management traits and general corporate needs.
Who is managing the offering?
A.G.P./Alliance Global Partners is acting as the sole placement agent for this transaction.
What are the expected earnings from the public offering?
Cibus expects to raise approximately $27.5 million from this offering.
How will this affect Cibus’ growth?
This funding is crucial for advancing Cibus’ research and development goals, positioning the company for sustained growth.
Can individuals invest in this offering?
The offering is available to institutional and strategic investors among others, following SEC regulations.
